Study to Investigate Safety, Tolerability and PK Following Single and Multiple Ascending Doses of AZD7295 in Japanese

A Phase I, Randomized, Double-Blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7295 Following Single and Multiple Ascending Oral Dose Administration in Healthy Male Japanese Subjects

The primary objective of this study is to investigate the safety and tolerability of single and multiple oral doses of AZD7295 in healthy male Japanese subjects. This will be done by comparing the effect of AZD7295 to placebo. The study will aslo investigate the absorption, distribution and disappearance of AZD7295 in the body.

Inclusion Criteria:

• Provision of signed, written and dated informed consent
• Healthy male Japanese volunteers aged 20-55 years
• BMI between 18 and 27 kg/m2
• Have negative screens for HIV, hepatitis B and C viruses and syphilis

Exclusion Criteria:

• Use of prescribed medication within 2 weeks prior to the dose of study medication
• Participation in another study that included drug treatment within 16 weeks before the start of the present study.
• History or presence of gastrointestinal, hepatic or renal disease or a condition known to interfere with absorption, distribution, metabolism or excretion of drugs.
• History of severe food or drug allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged relevant by the investigator.